Boiron S.A.

Boiron manufactures and markets homeopathic medicines. Homeopathic medicines are prepared from vegetable, animal, mineral, or chemical substances, which are diluted. Co. sells three types of products in 59 countries: Non-proprietary homeopathic medicines, OTC family medication specialties, and Other products. There are two large families of homeopathic medicines: Those associated with precise therapeutic indications and dosage, and those that do not mention a therapeutic indication or dosage. Co. supports homeopathy education and training organizations for healthcare professionals. Some of Co.'s brand names include Oscillococcinum®, Stodal®, S?datif PC®, and Coryzalia.
  • TickerBOI
  • ISINFR0000061129
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Alexandre Iatrides ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Rémi Adam

ODDO BHF Small & MIDCAP MORNING NEWS - 10/25/2019

...

Christophe-Raphaël Ganet

Boiron : CA T3 toujours baissier – OC : 31.5 € vs 34 €

>T3 en repli de 8.2% - Les ventes du T3 sont en baisse de 8.2% à 143.1 M€, essentiellement en France où les ventes sont en recul de 13.9%. En Europe, la situation est contrastée avec une hausse de l’activité en Italie et une baisse en Espagne alors que les États-Unis enregistrent une progression sensible de ses ventes.A 9 mois, la baisse des ventes atteint -8.4% (-9.1% à tcc) dont HNC : -8.9% et OTC : -8%.Boiron s’attend à une poursuite de la baisse du CA su...

Christophe-Raphaël Ganet

Boiron : Sales continue to trend downwards in Q3 – TP lowered to € 31.5 vs € 34

>Q3 sales down 8.2% - Sales fell by 8.2% in Q3 to € 143.1m, especially in France where they dropped by 13.9%. Performances in Europe were mixed, with sales growing in Italy but decreasing in Spain, whereas sales in the US rose significantly.So sales over the full 9 months are down by -8.4% (-9.1% at constant currencies), of which -8.9% for NPH (non-proprietary homeopathy) and -8% for OTC (over the counter) medicines.Boiron expects sales to contin...

Alexandre Iatrides ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Rémi Adam

ODDO BHF Small & MIDCAP MORNING NEWS - 25/10/2019

...

Christophe-Raphaël Ganet

Boiron : Can you do more with less?

In France, reimbursement of homeopathic treatments, which form Boiron's core business, will be completely discontinued as of 2021. In this report, we explore the likely impact on Boiron and the consequences on its business. Our forecasts are adjusted down (to more effectively factor in the reduced rate of reimbursement), as is our target price to € 31.5. - >The sword of Damocles has fallen - After several months of debate and an evaluation process conducted by the Hea...

Christophe-Raphaël Ganet

Boiron : CA T3 toujours baissier – OC : 31.5 € vs 34 €

>T3 en repli de 8.2% - Les ventes du T3 sont en baisse de 8.2% à 143.1 M€, essentiellement en France où les ventes sont en recul de 13.9%. En Europe, la situation est contrastée avec une hausse de l’activité en Italie et une baisse en Espagne alors que les États-Unis enregistrent une progression sensible de ses ventes.A 9 mois, la baisse des ventes atteint -8.4% (-9.1% à tcc) dont HNC : -8.9% et OTC : -8%.Boiron s’attend à une poursuite de la baisse du CA su...

Christophe-Raphaël Ganet

Boiron : Sales continue to trend downwards in Q3 – TP lowered to € 31.5 vs € 34

>Q3 sales down 8.2% - Sales fell by 8.2% in Q3 to € 143.1m, especially in France where they dropped by 13.9%. Performances in Europe were mixed, with sales growing in Italy but decreasing in Spain, whereas sales in the US rose significantly.So sales over the full 9 months are down by -8.4% (-9.1% at constant currencies), of which -8.9% for NPH (non-proprietary homeopathy) and -8% for OTC (over the counter) medicines.Boiron expects sales to contin...

Christophe-Raphaël Ganet

Boiron : Can you do more with less?

In France, reimbursement of homeopathic treatments, which form Boiron's core business, will be completely discontinued as of 2021. In this report, we explore the likely impact on Boiron and the consequences on its business. Our forecasts are adjusted down (to more effectively factor in the reduced rate of reimbursement), as is our target price to € 31.5. - >The sword of Damocles has fallen - After several months of debate and an evaluation process conducted by the Hea...

Christophe-Raphaël Ganet

Boiron : Est-il possible de « faire plus avec moins » ?

En France, l’homéopathie, cœur de métier de Boiron, va vers un déremboursement total à partir de 2021. Nous explorons ici ce que cela devrait induire chez Boiron et les conséquences économiques pour le groupe. Nos projections sont ajustées en baisse (pour mieux factoriser la baisse du remboursement), ainsi que notre OC à 31.5 €. - >L’épée de Damoclès est tombée - Après plusieurs mois de débats et une évaluation par la Haute Autorité de Santé, la France a décidé que l’h...

Christophe-Raphaël Ganet

Boiron : More uncertainty?

>Performance lagged in H1 in France and internationally - From our road show with the group, we note:1/ interim earnings (underlying operating profit: € 6m est. vs € 35.4m in H1 2018) were impacted by i/ the decline in business (-8.5%) notably due to an unfavourable comparison base in the US (lack of a winter pathology), attacks against homoeopathic medicine in a number of countries (France, Spain, Belgium, Italy) and a “generational effect” in France (the retire...

1 director bought

A director at Boiron bought 441 shares at 68.800EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Alexandre Iatrides ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Rémi Adam

ODDO BHF Small & MIDCAP MORNING NEWS - 10/25/2019

...

Alexandre Iatrides ...
  • Aurelien Sivignon
  • Baptiste Lebacq
  • Christophe Chaput
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Fatma Agnès Hamdani
  • Hela Zarrouk
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Rémi Adam

ODDO BHF Small & MIDCAP MORNING NEWS - 25/10/2019

...

Christophe-Raphaël Ganet ...
  • Jean-François Granjon
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 09/10/2019

...

Christophe-Raphaël Ganet ...
  • Jean-François Granjon
  • Olfa Taamallah
  • Yan Derocles

ODDO BHF Small & MIDCAP MORNING NEWS - 10/09/2019

...

Christophe-Raphaël Ganet ...
  • Jean-François Granjon
  • Philippe Ourpatian

ODDO BHF Small & MIDCAP MORNING NEWS - 06/28/2019

We are initiating coverage of SMCP, one of the world leaders in accessible luxury with a Buy recommendation and a target price of € 20.5. The group is known for delivering steady growth in each of its three brands. Taking the best of both worlds, it combines the benefits of luxury and fast fashion. We see the current valuation as an investment opportunity (EV/EBITDA 2019 of 6.3x, 30% discount vs. peers) in light of the group’s solid financial profile and significant growth potential, ...

Increased risk weighs on BOIRON SA, penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of BOIRON SA (FR), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date June 21, 2019, the closing price was EUR 37.35 and its target price was estimated at EUR 35.48.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Florian Béchaz

Boiron - Assemblée Générale des actionnaires du 16 mai 2019

Proxinvest attire l'attention des actionnaires sur deux points importants : Tout d'abord le conseil d'administration a un taux d'indépendance extrêmement faible avec 7,69% d'après Proxinvest. A ce moment-là Proxinvest regrette que la fin des mandats des trois administrateurs renouvelés cette année n'ait pas entrainé un sursaut de la société pour nommer en lieu et place des administrateurs indépendants. Ensuite le manque de communication des rémunérations est un grave manquement de la part de la société qui empêche les actionnaires d'avoir une vision globale des montants en jeu et de l'exigen...

Jehanne Leroy

Proxy Report - 17/05/2018

Proxinvest attire l'attention des actionnaires sur deux points importants : Tout d'abord le conseil d'administration a un taux d'indépendance extrêmement faible avec 8,33% d'après Proxinvest. A ce moment-là Proxinvest regrette que la fin des mandats des trois administrateurs renouvelés cette année n'ait pas entrainé un sursaut de la société pour nommer en lieu et place des administrateurs indépendants. Ensuite le manque de communication des rémunérations est un grave manquement de la part de la société qui empêche les actionnaires d'avoir une vision globale des montants en jeu et de l'exigen...

Boiron 2014

​Geol analyses are ESG (Environment, Social, Governance) analyses covering European large caps and small and mid caps, listed or non-listed. Those analyses, based on the ESG risks identified, show the qualitative and quantitative performance of issuers, in a ten-page synthesis.

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

Matthieu DRIOL

Short term view - BOIRON SA : The background trend is clearly bearish.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Short term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €50.19. Passing €68.90 would question the continuation of the fall.

Matthieu DRIOL

Analyse court terme - BOIRON SA : Le mouvement se poursuit.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 51,85 €, puis 50,19 €. Le franchissement de 68,90 € remettrait en cause la suite de la baisse.

Matthieu DRIOL

Medium term view - BOIRON SA : The movement goes on.

The background trend is clearly bearish. The movement goes on. The next target is at €51.85, then €41.74. Passing €88.94 would question the continuation of the fall.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch